Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

8月3日， 沃森生物 公告显示，公司与复旦大学、上海蓝鹊生物联合研发的RSV mRNA疫苗，已正式获国家药监局临床试验申请受理。这款基于自主研发mRNA技术平台的疫苗，瞄准的是预防RSV感染引起的下呼吸道相关疾病—— ...

作为儿科医生，曾经面对呼吸道合胞病毒（RSV）感染时，总有一种无力感。但今年略有不同，因为药物预防RSV感染已取得阶段性突破。去年国内开展注射的尼塞韦单抗（乐唯初），可有效减少婴幼儿重症RSV感染的发生。01药物预防目前有三种药物预防方式：1、单克隆 ...

Fact checked by Jennifer Klump Although respiratory syncytial virus (RSV) is often associated with children, adults can also get it. RSV usually causes mild, cold-like symptoms such as cough, ...

8月3日晚间沃森生物 (300142)公告，公司与复旦大学、上海蓝鹊生物医药有限公司等联合研发的呼吸道合胞病毒mRNA疫苗已向国家药品监督管理局申请临床试验，并于近日获得受理。该疫苗为基于自主研发的“mRNA疫苗技术平台”开发，用于预防呼吸道合胞病毒感染引起的下呼吸道相关疾病。

智通财经APP讯，沃森生物 (300142.SZ)发布公告，公司、复旦大学、上海蓝鹊生物医药有限公司 (以下简称“蓝鹊生物”)及公司子公司玉溪沃森生物技术有限公司、北京沃森创新生物技术有限公司联合研发的呼吸道合胞病毒mRNA疫苗 (以下简称“本疫苗”)向国家药品监督管理局申请临床试验，并于近日获得《受理通知书》。

随着新冠疫情的逐渐平息，呼吸道合胞病毒（RSV）作为一种常见的致病病毒，正逐渐引起家长们的关注。近日，云南沃森生物技术股份有限公司联合复旦大学和上海蓝鹊生物医药有限公司申请的呼吸道合胞病毒mRNA疫苗获得国家药品监督管理局的临床试验受理通知书。这一消息不仅为科学研究注入了新的活力，也为广大家长带来了保护孩子健康的新希望。

UK-based big pharma GlaxoSmithKline (GSK) has released its Q2 2025 results, which highlight the varying successes of its ...

Specialty Medicines delivered 15% growth to £3.3 billion, led by Respiratory, Immunology & Inflammation up 10%, Oncology up 42%, and HIV up 12%. CEO Emma Walmsley said the performance reflects “strong ...

Drugmaker GSK said on Wednesday that Q2 revenues had grown as a strong specialty medicines performance drove sales and core ...

Investing.com -- GSK (LON: GSK) on Wednesday raised its full-year earnings guidance after posting a 35% rise in ...

Renee Taylor relates her experiences as a dysphagia-specialist speech-language therapist working in aged care. She looks at what can be done to minimise risks and enhance quality of life for ...